Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin®), in Healthy Children and Adolescents 4 to 17 Years of Age.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- 100, Novartis Investigational Site
-
-
Queensland
-
Auchenflower, Queensland, Australia, 4066
- 108, Novartis Investigational Site
-
Sherwood, Queensland, Australia, 4075
- 107, Novartis Investigational Site
-
-
South Australia
-
North Adelaide, South Australia, Australia, 5006
- 104, Novartis Investigational Site
-
-
Victoria
-
Carlton, Victoria, Australia, 3010
- 103, Novartis Investigational Site
-
-
Western Australia
-
Subiaco, Western Australia, Australia, 6008
- 105, Novartis Investigational Site
-
-
-
-
Auckland
-
Takapuna, Auckland, New Zealand, 0622
- 151, Novartis Investigational Site
-
-
Christchurch
-
Beckenham, Christchurch, New Zealand, 8024
- 150, Novartis Investigational Site
-
-
-
-
Alabang
-
Muntinlupa City, Alabang, Philippines, 1781
- 250, Novartis Investigational Site
-
Muntinlupa City, Alabang, Philippines, 1781
- 251, Novartis Investigational Site
-
Muntinlupa City, Alabang, Philippines, 1781
- 254, Novartis Investigational Site
-
-
Ermita
-
Manila, Ermita, Philippines, 1001
- 253, Novartis Investigational Site
-
-
Sampaloc
-
Manila, Sampaloc, Philippines, 1001
- 252, Novartis Investigation Site
-
-
-
-
Muang
-
Khon Kaen, Muang, Thailand, 40002
- 201, Novartis Investigational Site
-
-
Rajathevi
-
Bangkok, Rajathevi, Thailand, 10400
- 200, Novartis Investigational Site
-
-
Siriraj
-
Bangkoknoi, Siriraj, Thailand, 10700
- 202, Novartis Investigational Site
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- 320, Novartis Investigational Site
-
-
Florida
-
Ponte Vedra, Florida, United States, 32081
- 312, Novartis Investigational Site
-
-
Kansas
-
Augusta, Kansas, United States, 67010
- 313, Novartis Investigational Site
-
Newton, Kansas, United States, 67114
- 305, Novartis Investigational Site
-
Wichita, Kansas, United States, 67205
- 302, Novartis Investigational Site
-
Wichita, Kansas, United States, 67207
- 301, Novartis Investigational Site
-
-
Nebraska
-
Fremont, Nebraska, United States, 68025
- 311, Novartis Investigational Site
-
-
North Carolina
-
Winston-salem, North Carolina, United States, 27103
- 308, Novartis Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44121
- 317, Novartis Investigational Site
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74127
- 309, Novartis Investigational Site
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- 314, Novartis Investigational Site
-
-
South Carolina
-
Mount Pleasant, South Carolina, United States, 29464
- 319, Novartis Investigational Site
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- 310, Novartis Investigational Site
-
Nashville, Tennessee, United States, 37203
- 318, Novartis Investigational Site
-
-
Utah
-
Salt Lake, Utah, United States, 84124
- 315, Novartis Investigational Site
-
Salt Lake City, Utah, United States, 84109
- 304, Novartis Investigational Site
-
Salt Lake City, Utah, United States, 84121
- 306, Novartis Investigational Site
-
South Jordan, Utah, United States, 84095
- 303, Novartis Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subjects 4-17 years of age
Exclusion Criteria:
- Subjects who are not healthy,
- Subjects who are pregnant or breast feeding,
- Subjects with a history of severe allergic reaction or allergic to any of the vaccine components.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TIVc
Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
|
|
|
Active Comparator: TIVf
Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number Of Subjects Reporting Solicited Local and Systemic Adverse Events and Other Indicators Of Reactogenicity After Any Vaccination.
Time Frame: Day 1 to Day 7 after any vaccination
|
Safety was assessed as the number of subjects who reported solicited local and systemic adverse events and other indicators of reactogenicity following two doses of either mammalian cell culture-derived or egg-derived trivalent influenza vaccination in subjects aged ≥4 To ≤17 Years.
|
Day 1 to Day 7 after any vaccination
|
|
Number Of Subjects Reporting Unsolicited Adverse Events After Any Vaccination.
Time Frame: Day 1 to Day49 for subjects aged ≥4 To ≤8 years not previously vaccinated. Day 1 to Day 38 for subjects aged ≥4 To ≤8 years previously vaccinated and all subjects aged ≥9 To ≤17 years.
|
Safety was assessed as the number of subjects who reported unsolicited adverse events following vaccination with either mammalian cell culture-derived or egg-derived trivalent influenza vaccination in subjects aged ≥4 To ≤17 Years.
|
Day 1 to Day49 for subjects aged ≥4 To ≤8 years not previously vaccinated. Day 1 to Day 38 for subjects aged ≥4 To ≤8 years previously vaccinated and all subjects aged ≥9 To ≤17 years.
|
|
Number Of Subjects Reporting Unsolicited Serious Adverse Events After Any Vaccination.
Time Frame: Day 1 to Day 183 for previously vaccinated subjects and Day 213 for not-previously vaccinated subjects
|
Safety was assessed as the number of subjects who reported serious adverse events (SAEs), medically attended AEs and new onset of chronic diseases (NOCD) in subjects aged ≥4 To ≤17 Years.
|
Day 1 to Day 183 for previously vaccinated subjects and Day 213 for not-previously vaccinated subjects
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- V58_31
- U1111-1139-9440 (Other Identifier: Universal Trial Number (UTN))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.